Potential drug–drug interaction in Mexican patients with schizophrenia

Abstract

Objective: The aim of this study was to observe potential drug–drug interactions in the medication of Mexican schizophrenic patients.

Methods: We performed a retrospective and cross-sectional study that was carried out in a psychiatric clinic. Only the prescriptions of patients with schizophrenia whose diagnoses were based on the DSM-IV instrument were included in this study. The Drug Interactions Checker software (http://www.drugs.com/drug_interactions.html) was used in this study to analyse potential drug–drug interactions.

Results: In total, 86 of 126 patients were at risk of potential drug–drug interactions. Haloperidol and biperiden was the most common drug pair of 232 pairs evaluated. In our study, 13.8% of drug–drug interaction showed a major level of severity, whereas in 83.2%, the interaction was moderate. Finally, central nervous system (CNS) depression and anticholinergic effect were the main possible effects of drug–drug interaction.

Conclusions: Our results revealed a high number of patients with schizophrenia receiving two or more drugs. The potential drug–drug interactions observed in the Mexican population are consistent with the concomitant use of antipsychotics, benzodiazepines, and antidepressants prescribed in schizophrenia that could cause central nervous system (CNS) depression and anticholinergic effect. Drug–drug interaction must be considered when the patient with schizophrenia is medicated.

Keywords:

• Drug–drug interaction
• schizophrenia
• Mexican population

Acknowledgements

The authors are grateful to the Psychiatry Unit of the Carraci Medical Group.

Disclosure statement

None to declare.